Cargando…

ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer

Invasive lobular breast cancer (ILC) is a special breast cancer (BC) subtype and is mostly hormone receptor (HR)-positive and ERBB2 non-amplified. Endocrine therapy restrains tumor proliferation and is the mainstay of lobular BC treatment. Mutation of ERBB2 has been associated with recurrent ILC. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grote, Isabel, Bartels, Stephan, Christgen, Henriette, Radner, Martin, Gronewold, Malte, Kandt, Leonie, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Graeser, Monika, Kuemmel, Sherko, Nitz, Ulrike, Harbeck, Nadia, Kreipe, Hans, Christgen, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708567/ https://www.ncbi.nlm.nih.gov/pubmed/35842479 http://dx.doi.org/10.1038/s41379-022-01130-7

Ejemplares similares

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

High frequency of lobular breast cancer in distant metastases to the orbit
por: Raap, Mieke, et al.
Publicado: (2015)

Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma
por: Sflomos, George, et al.
Publicado: (2023)

Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
por: Christgen, Matthias, et al.
Publicado: (2021)

E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements
por: Christgen, Matthias, et al.
Publicado: (2020)

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

Chromosome 2q gain and epigenetic silencing of GATA3 in microglandular adenosis of the breast
por: Radner, Martin, et al.
Publicado: (2020)

Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis
por: Christgen, Matthias, et al.
Publicado: (2016)

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial
por: Graeser, Monika, et al.
Publicado: (2021)

Is Upregulation of BCL2 a Determinant of Tumor Development Driven by Inactivation of CDH1/E-Cadherin?
por: Karch, Inga, et al.
Publicado: (2013)

Clinical validity and clinical utility of Ki67 in early breast cancer
por: Kreipe, Hans, et al.
Publicado: (2022)

The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2020)

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2017)

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
por: Nitz, Ulrike, et al.
Publicado: (2019)

Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
por: van Agthoven, Ton, et al.
Publicado: (2015)

Lobular breast cancer: molecular basis, mouse and cellular models
por: Christgen, Matthias, et al.
Publicado: (2015)

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
por: Dowsett, Mitch, et al.
Publicado: (2020)

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
por: Nitz, Ulrike, et al.
Publicado: (2020)

Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors
por: Christgen, Matthias, et al.
Publicado: (2021)

Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid‐papillary carcinoma
por: Christgen, Matthias, et al.
Publicado: (2017)

Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18
por: Raap, M., et al.
Publicado: (2021)

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2(+)/HR(−) Trial
por: Graeser, Monika, et al.
Publicado: (2023)

Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology
por: Hasemeier, Britta, et al.
Publicado: (2008)

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
por: de Gregorio, Amelie, et al.
Publicado: (2022)

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials
por: Graeser, Monika, et al.
Publicado: (2021)

Limited Value of KAI1/CD82 Protein Expression as a Prognostic Marker in Human Gastric Cancer
por: Knoener, Maximilian, et al.
Publicado: (2012)

Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer
por: Leo, Fabian, et al.
Publicado: (2016)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Identification of differentially expressed microRNAs in human male breast cancer
por: Lehmann, Ulrich, et al.
Publicado: (2010)

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
por: Sflomos, George, et al.
Publicado: (2021)

Frequent and Distinct Aberrations of DNA Methylation Patterns in Fibrolamellar Carcinoma of the Liver
por: Tränkenschuh, Wolfgang, et al.
Publicado: (2010)

Hypermethylation of cyclin D(2 )and DAP kinase is associated with the lobular subtype of breast cancer
por: Lehmann, U, et al.
Publicado: (2005)

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
por: Hofmann, Daniel, et al.
Publicado: (2013)

Exploring the spatial dimension of estrogen and progesterone signaling: detection of nuclear labeling in lobular epithelial cells in normal mammary glands adjacent to breast cancer
por: Grote, Anne, et al.
Publicado: (2014)

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
por: Harbeck, Nadia, et al.
Publicado: (2021)

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas
por: Deniziaut, Gabrielle, et al.
Publicado: (2016)

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2019)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rh3lpbu775ggbmcg2k4eb54hl5